Compare GSK plc (GSK) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Match Group Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Match Group Inc trades at $41.2 (market cap $9.53B). The key difference: GSK plc is far larger — about 9.6× Match Group Inc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Match Group Inc for 115 Days on average.
| GSK | MTCH | |
|---|---|---|
Market Cap | $91.88B | $9.53B |
Volume | 7,730,529 | 3,228,794 |
Sector | Health | Media |
52-Week High | $61.18 | $44.40 |
52-Week Low | $43.24 | $28.90 |
Typical Hold Time | 93 Days | 115 Days |
Enterprise Value | $111.88B | $12.49B |
Dividend Yield | 3.9% | 1.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Match Group (MTCH) trades at $41.09, up 0.56% with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with $3.49B revenue, 20.17% net margin, and improving cash flow trends. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 missed. Analyst sentiment remains positive with 53% buy ratings and a $42.29 consensus target, just above current levels. The stock faces competition and debt concerns but benefits from Hinge's growth and Tinder's AI initiatives.
MTCH presents a balanced opportunity with solid profitability and cash generation offset by high debt levels. Upside potential exists from product innovation and margin expansion, though investor caution is warranted given competitive pressures and the stock's proximity to analyst targets. The company's dominant market position and improving operational efficiency support long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
